Literature DB >> 16284920

Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.

Nidal H Al-Huniti1, John A Widness, Robert L Schmidt, Peter Veng-Pedersen.   

Abstract

Changes in the reticulocyte subtype distribution (high, medium and low reticulocytes count (HR, MR, LR)) measured by flow cytometry following phlebotomy-induced stress erythropoiesis (abruptly dropping hemoglobin to 3-4 g/dl over 4-5 hr) and the pharmacodynamic (PD) relationship to the stimulated erythropoietin (EPO) was investigated in sheep. A PD model was developed that describes the relationship between EPO and the reticulocyte maturity distribution fractions (r=0.95+/-0.02, mean +/- SD). The lag-time between EPO activation of erythroid progenitor cells and the subsequent increase in the least mature HR fraction in the peripheral circulation was 0.72 +/- 0.08 days. The mean transition times (in days) for all three reticulocyte fractions changed at baseline from, T(HR) : 0.09 +/- 0.06, T(MR) : 0.06 +/- 0.04, and T(LR) : 0.46 +/- 0.24 to T(HR) : 0.13 +/- 0.08, T(MR) : 0.29 +/- 0.15, and T(LR) : 2.3 +/- 0.24 under stress erythropoiesis. The total mean residence time for a reticulocyte in the peripheral circulation, T(total) (T(HR) + T(MR) + T(LR)), increased from 0.60 +/- 0.33 days under basal to 2.8 +/- 0.09 days during stress erythropoiesis. The statistically significant increase observed for T(LR) and T(total) supports the hypothesis that stress erythropoiesis perturbs the mean reticulocyte transition times. A correlation analysis between various new, proposed metrics involving the HR, MR and LR fractions and the total reticulocyte count, with the latter indicative of stress erythropoiesis at higher total counts, revealed a highly significant correlation indicating these new metrics may be a valuable adjunct to the reticulocyte maturation index (RMI) and the immature reticulocyte fractions index (IRF) previously used in assessing erythropoietic activity in response to anemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284920     DOI: 10.1007/s10928-005-0009-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  35 in total

1.  The maturation of reticulocytes. II. Life-span of red cells originating from stress reticulocytes.

Authors:  A Shimada
Journal:  Acta Med Okayama       Date:  1975-08       Impact factor: 0.892

2.  Immature reticulocytes as an early predictor of engraftment in autologous and allogeneic bone marrow transplantation.

Authors:  J F A Noronha; C A De Souza; A C Vigorito; F J P Aranha; R Zulli; E C M Miranda; H Z W Grotto
Journal:  Clin Lab Haematol       Date:  2003-02

3.  Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients.

Authors:  O Sowade; B Sowade; K Brilla; W Franke; P Stephan; J Gross; P Scigalla; H Warnke
Journal:  Am J Hematol       Date:  1997-06       Impact factor: 10.047

4.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 5.  Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting.

Authors:  M Pradella; I Cavill; G d'Onofrio
Journal:  Clin Lab Haematol       Date:  1996-12

6.  Utility of reticulocyte maturation parameters in the differential diagnosis of macrocytic anemias.

Authors:  A Torres Gomez; J Casaño; J Sánchez; E Madrigal; F Blanco; M A Alvarez
Journal:  Clin Lab Haematol       Date:  2003-10

7.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Mary C Wacholtz; Neil Minton; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

Review 8.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01

9.  Flow cytometric reticulocyte quantification in the evaluation of hematologic recovery. Spanish Multicentric Study Group for Hematopoietic Recovery.

Authors: 
Journal:  Eur J Haematol       Date:  1994-11       Impact factor: 2.997

10.  Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia.

Authors:  N H Al-Huniti; J A Widness; R L Schmidt; P Veng-Pedersen
Journal:  J Pharmacol Exp Ther       Date:  2004-02-26       Impact factor: 4.030

View more
  14 in total

1.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

2.  Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.

Authors:  Juan José Pérez-Ruixo; Wojciech Krzyzanski; Jeremy Hing
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  A 'bottom-up' approach for endo-PK/PD analysis.

Authors:  S Neelakantan; J A Widness; R L Schmidt; P Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2006-10       Impact factor: 1.627

4.  Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.

Authors:  Mohammed H El-Komy; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-01-05       Impact factor: 3.922

5.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

6.  An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2007-02-21       Impact factor: 4.200

7.  Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.

Authors:  Kevin J Freise; John A Widness; Jeffrey L Segar; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pharm Res       Date:  2007-04-25       Impact factor: 4.200

8.  Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

9.  Models for the red blood cell lifespan.

Authors:  Rajiv P Shrestha; Joseph Horowitz; Christopher V Hollot; Michael J Germain; John A Widness; Donald M Mock; Peter Veng-Pedersen; Yossi Chait
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-04-02       Impact factor: 2.745

10.  Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-14       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.